...
首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential
【24h】

Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential

机译:丹红注射心血管和脑血管病:药理作用,分子机制和治疗潜力

获取原文
获取原文并翻译 | 示例

摘要

Cardiovascular and cerebrovascular diseases are the main cause of mortality worldwide, currently with less than optimum therapeutic options. Danhong injection (DHI) is a medicinal preparation based on two eminent Chinese herbal medicines, Salviae Miltiorrhizae (Dan Shen; family: Lamiaceae) and Flos Carthami (Hong Hua; family: Compositae/Asteraceae). DHI has been mainly used in the clinical therapy of cardiovascular (such as acute coronary syndrome and angina pectoris) and cerebrovascular diseases (such as stroke) in China for many years. The pharmacological properties of DHI include anti-inflammatory, anti-oxidant, anti-coagulatory, hypolipidemic, anti-apoptotic, vasodilatory, and angiogenesis-promoting actions. DHI offers a safe and effective therapeutic agent against cardiovascular and cerebrovascular diseases by modulating multiple disease-relevant signaling pathways and molecular targets. Herein, we provide a comprehensive review of the phytochemistry, therapeutic effects, molecular mechanisms, and adverse reactions of DHI in cardiovascular and cerebrovascular diseases. We also highlight the latest pharmacological advances and therapeutic potential of this promising herb derived cardiovascular drug preparation.
机译:心血管和脑血管疾病是全世界死亡率的主要原因,目前尚未少于最佳治疗选择。丹洪注射(DHI)是一种基于两种杰出的中草药,丹参米尔蒂希萨诸塞州的药用制剂(Dan Shen;家族:LamiCeae)和Flos Carthami(Hong Hua;家族:Compositae / Asteraceae)。 DHI已主要用于中国心血管(如急性冠状动脉综合征和心绞痛)和中国脑血管疾病(如中风)多年的临床治疗。 DHI的药理学性质包括抗炎,抗氧化剂,抗凝,低血脂,抗凋亡,血管舒张和血管生成促进作用。 DHI通过调节多种疾病相关的信号通路和分子靶标,提供一种安全有效的治疗剂,防止心血管和脑血管疾病。在此,我们对心血管和脑血管疾病的DHI的植物化学,治疗效果,分子机制和不良反应提供全面的审查。我们还突出了这一有前途的草药衍生的心血管药物制剂的最新药理学进步和治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号